Chronic DiseaseTAIGOLD-CDMNCT07308314
Taining Golden Lake Comprehensive Chronic Disease Management Initiative
An observational study of Chronic Disease and Chronic Disease Management, run by First Affiliated Hospital of Fujian Medical University at 1 site in China.
Trial summary
This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Disease, Chronic Disease Management, Hypertension
- How many people
- 20,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2025to 1 Jul 2030
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of community-dwelling adult residents of Taining County, a mountainous region in Fujian Province, China. Eligible participants are men and women aged 18 years and older who have lived in the county for at least 6 months and are expected to remain for the next 3 years. A total of at least 20,000 participants will be enrolled at baseline through community-based recruitment and household registration systems. The population reflects the demographic and health characteristics of a rural county with a relatively high proportion of older adults and a growing burden of chronic diseases such as hypertension, diabetes, and cardiovascular disease.
Who may be able to join
- Age ≥18 years, male or female.
- Resident of Taining County for ≥6 months and expected to remain in the county for at least the next 3 years.
- Full civil capacity and able to understand study procedures.
- Willing to voluntarily participate and provide written informed consent.
- Able to complete baseline survey and follow-up visits.
Who cannot join
- Refusal to sign informed consent.
- Severe psychiatric disorders or cognitive impairment preventing participation.
- End-stage disease with expected survival <1 year.
- Long-term migrants (≥6 months per year outside the county), unable to guarantee follow-up.
- Participation in other clinical studies that may interfere with this research.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350011
Hailin Zhang, 0086059187981637, 824224843@qq.com
About this study
This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.
Read the detailed description
China is undergoing rapid population aging, with chronic non-communicable diseases (NCDs) becoming the leading cause of death and disability. Taining County, located in a mountainous area of Fujian Province, faces a higher-than-average aging population and a growing burden of hypertension, diabetes, dyslipidemia, and cardiovascular diseases. Early detection and standardized management remain insufficient, and healthcare resources are limited. This study will establish a prospective cohort covering ≥20,000 residents, integrating demographic, lifestyle, clinical, laboratory, and imaging data. Active follow-up will be conducted annually, complemented by passive follow-up through local healthcare and death registry systems. The study will (1) identify epidemiological features and risk factors of common chronic diseases, (2) explore multimorbidity and aging trajectories, and (3) develop a replicable "Taining Model" for chronic disease prevention and management at the county level. The results will provide an evidence base for public health decision-making and chronic disease control strategies in similar rural and mountainous regions.
- Conditions
- Chronic Disease, Chronic Disease Management, Hypertension, Diabetes Mellitus, Dyslipidemias, Frailty
- Keywords
- Chronic Disease Management, Prospective Cohort, Hypertension, Diabetes Mellitus, Dyslipidemia, Cardiovascular Disease, Frailty, Sarcopenia, Aging, Healthy Aging
- Medical subject headings
- Chronic Disease, Hypertension, Diabetes Mellitus, Dyslipidemias, Frailty, Sarcopenia, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Taining County Resident Cohort | A community-based cohort of ≥20,000 adult residents (aged 18 years and older) living in Taining County, Fujian Province, China. Participants will undergo baseline assessments including questionnaires, physical examinations, laboratory tests, imaging, and biospecimen collection. Annual follow-up (active and passive) will be conducted for 3 years to record incidence of chronic diseases, functional status, and aging-related outcomes. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Major Adverse Cardiovascular Events (MACE)
Composite outcome including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Events will be ascertained through active follow-up and confirmed using medical records and hospital discharge summaries.
Measured: Up to 36 months
Secondary outcomes (7)
Incidence of Cardiovascular and Cerebrovascular Events
New onset of coronary heart disease, stroke, or heart failure, identified through follow-up visits and confirmed using medical records.
Measured: Up to 36 months
Heart Failure-Related Rehospitalization Rate
Rehospitalization due to worsening heart failure among participants diagnosed with heart failure, confirmed by hospital admission records.
Measured: Up to 36 months
Bleeding Events
Occurrence of clinically significant bleeding events, including gastrointestinal bleeding and other major or clinically relevant non-major bleeding, identified through follow-up and medical records.
Measured: Up to 36 months
Health Economics Outcomes
Direct medical costs, hospitalization expenses, outpatient visit costs, medication costs, and health service utilization related to chronic disease management, collected from medical records and insurance data.
Measured: Up to 36 months
Cognitive Function Outcomes
Changes in cognitive function assessed using standardized cognitive screening tools administered at baseline and during follow-up.
Measured: Baseline and annual follow-up (Year 1-3)
Cancer Incidence and Cancer-Related Outcomes
Newly diagnosed malignant tumors and cancer-related outcomes, identified through self-report and confirmed by medical records or cancer registry data.
Measured: Up to 36 months
All-Cause Mortality
Death from any cause, confirmed through medical records and the local death registry system.
Measured: Up to 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2025
- Study start1 Aug 2025
- Primary completion1 Aug 2029 (estimated)
- Study completion1 Jul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Chronic DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dajun Chai, First Affiliated Hospital of Fujian Medical University
- Investigators
- Dajun Chai, MD, Principal investigator, First Affiliated Hospital of Fujian Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07308314
- Sponsor's protocol ID
- MRCTA,ECFAH of FMU[2025]950
- Acronym
- TAIGOLD-CDM
- Status last verified
- Oct 2026
- First submitted
- 15 Dec 2025
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data, including demographic information, clinical characteristics, imaging parameters ECG data, laboratory test results, biospecimen profiles and follow-up outcomes, will be shared.
Publications
Chen L, Li X, Lv Y, Tan X, Zhong VW, Rong S, Liu G, Liu L. Physical frailty, adherence to ideal cardiovascular health and risk of cardiovascular disease: a prospective cohort study. Age Ageing. 2023 Jan 8;52(1):afac311. doi: 10.1093/ageing/afac311.
PubMed 36626327Hu L, Li J, Tang Z, Gong P, Chang Z, Yang C, Ma T, Jiang S, Yang C, Zhang T. How does biological age acceleration mediate the associations of obesity with cardiovascular disease? Evidence from international multi-cohort studies. Cardiovasc Diabetol. 2025 May 14;24(1):209. doi: 10.1186/s12933-025-02770-0.
PubMed 40369582Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, De Bacquer D, Ballantyne CM, Bernabe-Ortiz A, Bobak M, Brenner H, Carrillo-Larco RM, de Lemos J, Dobson A, Dorr M, Donfrancesco C, Drygas W, Dullaart RP, Engstrom G, Ferrario MM, Ferrieres J, de Gaetano G, Goldbourt U, Gonzalez C, Grassi G, Hodge AM, Hveem K, Iacoviello L, Ikram MK, Irazola V, Jobe M, Jousilahti P, Kaleebu P, Kavousi M, Kee F, Khalili D, Koenig W, Kontsevaya A, Kuulasmaa K, Lackner KJ, Leistner DM, Lind L, Linneberg A, Lorenz T, Lyngbakken MN, Malekzadeh R, Malyutina S, Mathiesen EB, Melander O, Metspalu A, Miranda JJ, Moitry M, Mugisha J, Nalini M, Nambi V, Ninomiya T, Oppermann K, d'Orsi E, Pajak A, Palmieri L, Panagiotakos D, Perianayagam A, Peters A, Poustchi H, Prentice AM, Prescott E, Riserus U, Salomaa V, Sans S, Sakata S, Schottker B, Schutte AE, Sepanlou SG, Sharma SK, Shaw JE, Simons LA, Soderberg S, Tamosiunas A, Thorand B, Tunstall-Pedoe H, Twerenbold R, Vanuzzo D, Veronesi G, Waibel J, Wannamethee SG, Watanabe M, Wild PS, Yao Y, Zeng Y, Ziegler A, Blankenberg S. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med. 2023 Oct 5;389(14):1273-1285. doi: 10.1056/NEJMoa2206916. Epub 2023 Aug 26.
PubMed 37632466Moturi S, Ghosh-Choudhary SK, Finkel T. Cardiovascular disease and the biology of aging. J Mol Cell Cardiol. 2022 Jun;167:109-117. doi: 10.1016/j.yjmcc.2022.04.005. Epub 2022 Apr 11.
PubMed 35421400Liberale L, Badimon L, Montecucco F, Luscher TF, Libby P, Camici GG. Inflammation, Aging, and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 Mar 1;79(8):837-847. doi: 10.1016/j.jacc.2021.12.017.
PubMed 35210039Hu C. Prevention of cardiovascular disease for healthy aging and longevity: A new scoring system and related "mechanisms-hallmarks-biomarkers". Ageing Res Rev. 2025 May;107:102727. doi: 10.1016/j.arr.2025.102727. Epub 2025 Mar 15.
PubMed 40096912da Silva PFL, Schumacher B. Principles of the Molecular and Cellular Mechanisms of Aging. J Invest Dermatol. 2021 Apr;141(4S):951-960. doi: 10.1016/j.jid.2020.11.018. Epub 2021 Jan 29.
PubMed 33518357Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, Bautmans I, Widschwendter M, Ding J, Fleming A, Mannick J, Han JJ, Zhavoronkov A, Barzilai N, Kaeberlein M, Cummings S, Kennedy BK, Ferrucci L, Horvath S, Verdin E, Maier AB, Snyder MP, Sebastiano V, Gladyshev VN. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023 Aug 31;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003.
PubMed 37657418Nash DB. The Future of Chronic Disease Management. Popul Health Manag. 2023 Aug;26(S1):S2-S3. doi: 10.1089/pop.2023.0128. No abstract available.
PubMed 37603800Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, Meribole ES, Lawal SO, Okenwa CJ, Okafor GC, Umeh ED, Mutalib OO, Opashola KA, Fatoye JO, Awotoye TI, Tobih-Ojeanelo JI, Ramon-Yusuf HI, Olanrewaju A, Afuh RN, Adenikinju J, Amosu O, Yusuf A. Comprehensive review of current management guidelines of chronic kidney disease. Medicine (Baltimore). 2023 Jun 9;102(23):e33984. doi: 10.1097/MD.0000000000033984.
PubMed 37335639Chan SW. Chronic Disease Management, Self-Efficacy and Quality of Life. J Nurs Res. 2021 Feb 1;29(1):e129. doi: 10.1097/JNR.0000000000000422. No abstract available.
PubMed 33427791Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36. doi: 10.1164/rccm.202009-3533SO.
PubMed 33146552